Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression.
The effect of HIV-related immunosuppression and antiretroviral therapy on the reactivation of latent hepatitis B virus (HBV) infection is unclear. We report four patients with advanced HIV-related immunosuppression and abnormal liver function tests who had evidence of HBV reactivation. Reclearance of hepatitis B occurred in two cases with HIV treatment regimens not containing lamivudine, suggesting that improved immune function may be responsible. In three cases, HBV reactivation was recognized during investigation for abnormal liver function initially attributed to drug toxicity. The possibility of HBV reactivation must be considered in the differential diagnosis of abnormal liver function in cases with advanced HIV.
Clark
S J
SJ
Department of Liver Studies, King's College Hospital, Denmark Hill, London, UK. Sarah.Clark@stgeorges.nhs.uk
Creighton
S
S
Horner
M
M
Smith
H M
HM
Portmann
B
B
Taylor
C
C
Cramp
M E
ME
D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology*; D006509:Hepatitis B / Q000150:complications*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D014775:Virus Activation; D017735:Virus Latency